Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

and streamline your search for investment opportunities using Tipranks' Stock Screener Michael Nedelcovych’s rating is based on Novo Nordisk’s strategic acquisition of Catalent, which ...

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues ... “We continue to make progress on our strategic aspirations,” he added. “Our focus in 2024 will be on ...

Danish pharmaceutical giant Novo Nordisk posted bumper profits ... "We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will ...

today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will ...